Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Tim EisenEleni FrangouBhavna OzaAlastair W S RitchieBenjamin SmithRichard S KaplanIan D DavisMartin R StocklerLaurence AlbigesBernard EscudierJames M G LarkinAxel BexSteven JoniauBarry HancockGregers G HermannJoaquim BellmuntElizabeth HodgkinsonGrant D StewartJim BarberJanet BrownRhona McMeneminPaul NathanLisa M PickeringMahesh K B ParmarAngela MeadePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Sorafenib should not be used as adjuvant therapy for RCC. Active surveillance remains the standard of care for patients at intermediate or high risk of recurrence after nephrectomy and is the appropriate control of our current international adjuvant RCC trial, RAMPART.